AbbVie Inc.

ABBV-N

NYSE:ABBV

104.87
0.83 (0.79%)
AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories.
More at Wikipedia

Analysis and Opinions about ABBV-N

Signal
Opinion
Expert
BUY
BUY
November 19, 2020
You would own it for the strong yield at 5.25%. Valuation is quite cheap relative to peers. Good earnings growth and dividend growth. They raised their guidance which is positive. The split congress helps this name since pushing drug prices down will be harder.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 19, 2020
You would own it for the strong yield at 5.25%. Valuation is quite cheap relative to peers. Good earnings growth and dividend growth. They raised their guidance which is positive. The split congress helps this name since pushing drug prices down will be harder.
BUY
BUY
October 23, 2020

Likes it. A spin-off of Abbott Labs. They have made a purchase of Allergan that diluted the concentration of Humira. The company will get its legs so buy it and be patient.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
October 23, 2020

Likes it. A spin-off of Abbott Labs. They have made a purchase of Allergan that diluted the concentration of Humira. The company will get its legs so buy it and be patient.

TOP PICK
TOP PICK
October 20, 2020

A sort of contrarian call. Humera is their primary drug (US$19.5 billion annually) used for various immunology disorders. Competitors will nip at their heels here, of course, given that success. They have this drug through 2023. As importantly, they bought Allergan, makers of botox, which is executing. Pays a .5.5% dividend and trades at 7x earnings. There's a disconnect between company value/performance and market perception. A great balance sheet to support the dividend. (Analysts’ price target is $110.26)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
October 20, 2020

A sort of contrarian call. Humera is their primary drug (US$19.5 billion annually) used for various immunology disorders. Competitors will nip at their heels here, of course, given that success. They have this drug through 2023. As importantly, they bought Allergan, makers of botox, which is executing. Pays a .5.5% dividend and trades at 7x earnings. There's a disconnect between company value/performance and market perception. A great balance sheet to support the dividend. (Analysts’ price target is $110.26)

DON'T BUY
DON'T BUY
October 14, 2020

Owns Abbott Labs instead, as it's more diversified. ABBV is pure pharma. They need to broaden reliance on a few key drugs.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
October 14, 2020

Owns Abbott Labs instead, as it's more diversified. ABBV is pure pharma. They need to broaden reliance on a few key drugs.

TOP PICK
TOP PICK
September 30, 2020

Dominance of Humira on revenues had given them pause. Since then, it acquired Allergan, which diluted the concentration of Humera. Metrics are wonderful. 12% free cash flow yield. Trades at less than 10x earnings. Great dividend. Lots of runway ahead. Elective surgeries will come back. Anticipate $12.50 EPS this year, and more next. Yield is 5.42%. (Analysts’ price target is $109.35)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
September 30, 2020

Dominance of Humira on revenues had given them pause. Since then, it acquired Allergan, which diluted the concentration of Humera. Metrics are wonderful. 12% free cash flow yield. Trades at less than 10x earnings. Great dividend. Lots of runway ahead. Elective surgeries will come back. Anticipate $12.50 EPS this year, and more next. Yield is 5.42%. (Analysts’ price target is $109.35)

BUY
BUY
September 30, 2020
It hasn't been doing well, because it has an expiration of 2020 for one its key drugs, Humira, and the pandemic has limited elective surgery Botox, which AbbVie owns. These issues will get resolved and the stock will go to $100.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
September 30, 2020
It hasn't been doing well, because it has an expiration of 2020 for one its key drugs, Humira, and the pandemic has limited elective surgery Botox, which AbbVie owns. These issues will get resolved and the stock will go to $100.
BUY
BUY
August 27, 2020

ABBV vs. PFE Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 27, 2020

ABBV vs. PFE Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.

BUY
BUY
August 26, 2020

Likes the sector. Also owns Merck, Regeneron, and LZAGY. ABBV is in immunology and oncology. 8x forward earnings, 8% growth rate, pretty fair valuation. Also involved in Covid antibodies. Likes the combination of decent growth and nice dividend of about 5%.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 26, 2020

Likes the sector. Also owns Merck, Regeneron, and LZAGY. ABBV is in immunology and oncology. 8x forward earnings, 8% growth rate, pretty fair valuation. Also involved in Covid antibodies. Likes the combination of decent growth and nice dividend of about 5%.

BUY
BUY
July 28, 2020

Allan Tong’s Discover Picks The good thing about this drugmaker is that its arthritis drug, Humira, has been a runaway success, making up 63% of company revenues. The problem with AbbVie is also Humira–it loses patent protection in American in 2023. Read Top 4 BNN Stock Picks to Buy this Summer for our full analysis.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 28, 2020

Allan Tong’s Discover Picks The good thing about this drugmaker is that its arthritis drug, Humira, has been a runaway success, making up 63% of company revenues. The problem with AbbVie is also Humira–it loses patent protection in American in 2023. Read Top 4 BNN Stock Picks to Buy this Summer for our full analysis.

BUY
BUY
July 9, 2020

Healthcare is one of his favourite sectors. 10% growth rate. Value is there. Beta is below S&P. Dividend of 4.7% or so. Good drug pipeline. Covid R&D is pushing the stock up. Allergan acquisition will give EPS a boost.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 9, 2020

Healthcare is one of his favourite sectors. 10% growth rate. Value is there. Beta is below S&P. Dividend of 4.7% or so. Good drug pipeline. Covid R&D is pushing the stock up. Allergan acquisition will give EPS a boost.

BUY
BUY
June 17, 2020
It pays a nice dividend and the company is committed to it. The company is hitting its stride. It made a big acquisition that introduced a new business enterprise, focusing on botox. They have the most successful drug in America -- Humara. This is helping to reduce their dependency on revenue from Humara. He recommends it here. Yield 5%
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
June 17, 2020
It pays a nice dividend and the company is committed to it. The company is hitting its stride. It made a big acquisition that introduced a new business enterprise, focusing on botox. They have the most successful drug in America -- Humara. This is helping to reduce their dependency on revenue from Humara. He recommends it here. Yield 5%
COMMENT
COMMENT
June 12, 2020

JNJ vs ABBV? He likes JNJ as a long term winner. It may be too expensive. ABBV was a risky company until they purchased Allergan and diversified their business more. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. They are still tethered to Humara, which has a lot of generics being developed. He would favor ABBV, although it is a little riskier than JNJ.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
June 12, 2020

JNJ vs ABBV? He likes JNJ as a long term winner. It may be too expensive. ABBV was a risky company until they purchased Allergan and diversified their business more. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. They are still tethered to Humara, which has a lot of generics being developed. He would favor ABBV, although it is a little riskier than JNJ.

TOP PICK
TOP PICK
May 12, 2020

Loves it. He shied away from it in the past because its product offering was concentrated. When they were spun-off from Abbot Labs, it was spun-off with the successful rheumetory arthritis drug, Humira, but the drug made up 63% of company revenues, so the risk was high. In the last year, ABBV bought Allergan which should close this quarter after European and US approvals. Allergan is known for Botox. Together, this will be a great company. It trades at less than 9x PE. Pays a fine 5.5% dividend. The merger is accretive immediately. Great freee cash flow. However, they paid $60 billion for Allergan, but they have the cash flow to pay down that debt at very low interest rates. (Analysts’ price target is $96.33)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
May 12, 2020

Loves it. He shied away from it in the past because its product offering was concentrated. When they were spun-off from Abbot Labs, it was spun-off with the successful rheumetory arthritis drug, Humira, but the drug made up 63% of company revenues, so the risk was high. In the last year, ABBV bought Allergan which should close this quarter after European and US approvals. Allergan is known for Botox. Together, this will be a great company. It trades at less than 9x PE. Pays a fine 5.5% dividend. The merger is accretive immediately. Great freee cash flow. However, they paid $60 billion for Allergan, but they have the cash flow to pay down that debt at very low interest rates. (Analysts’ price target is $96.33)

WAIT
WAIT
February 6, 2020
Trades at 38x earnings. Great dividend yield. Prefers something like JNJ, as it has 3 divisions. With pharma, you need these blockbuster drugs. If the pipeline is weak, the stock falls. Much more difficult to own in an election year, as they're the easiest scapegoat. Pharma usually pops up after an election.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 6, 2020
Trades at 38x earnings. Great dividend yield. Prefers something like JNJ, as it has 3 divisions. With pharma, you need these blockbuster drugs. If the pipeline is weak, the stock falls. Much more difficult to own in an election year, as they're the easiest scapegoat. Pharma usually pops up after an election.
BUY
BUY
February 3, 2020
He likes it. There's a new uptrend after a long downtrend since early 2018. He's like to see strong volumes and support at $80. If so, it could touch $90.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 3, 2020
He likes it. There's a new uptrend after a long downtrend since early 2018. He's like to see strong volumes and support at $80. If so, it could touch $90.
Showing 1 to 15 of 67 entries

AbbVie Inc.(ABBV-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 10

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 11

Stockchase rating for AbbVie Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

AbbVie Inc.(ABBV-N) Frequently Asked Questions

What is AbbVie Inc. stock symbol?

AbbVie Inc. is a American stock, trading under the symbol ABBV-N on the New York Stock Exchange (ABBV). It is usually referred to as NYSE:ABBV or ABBV-N

Is AbbVie Inc. a buy or a sell?

In the last year, 11 stock analysts published opinions about ABBV-N. 10 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for AbbVie Inc..

Is AbbVie Inc. a good investment or a top pick?

AbbVie Inc. was recommended as a Top Pick by Stan Wong on 2020-11-19. Read the latest stock experts ratings for AbbVie Inc..

Why is AbbVie Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is AbbVie Inc. worth watching?

11 stock analysts on Stockchase covered AbbVie Inc. In the last year. It is a trending stock that is worth watching.

What is AbbVie Inc. stock price?

On 2020-12-02, AbbVie Inc. (ABBV-N) stock closed at a price of $104.865.